Virotek Biosciences

Virotek Biosciences is a Canadian biotechnology company specializing in advanced genomic and multi-omic diagnostic solutions. Founded in 2020 and headquartered in Markham, Ontario, the company initially developed the CoviSafe™ at-home saliva test for COVID-19 before expanding into mental health and oncology diagnostics. Virotek operates a high-throughput specialty laboratory and was the first in Canada to implement the AVITI24™ 5D multi-omic platform, which integrates RNA, protein, and spatial data. Their lead diagnostic programs focus on blood-based testing for bipolar disorder and early cancer detection, utilizing proprietary AI-driven cloud computing to deliver clinically validated insights. The company serves healthcare providers and biopharmaceutical partners to improve patient stratification and clinical trial outcomes.